|
1
|
Staker BL, Hjerrild K, Feese MD, Behnke
CA, Burgin AB and Stewart L: The mechanism of topoisomerase I
poisoning by a camptothecin analog. Proc Natl Acad Sci USA.
99:15387–15392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pommier Y and Cushman M: The
indenoisoquinoline noncamptothecin topoisomerase I inhibitors:
update and perspectives. Mol Cancer Ther. 8:1008–1014. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sáchez C, Médez C and Salas JA:
Indolocarbazole natural products: occurrence, biosynthesis, and
biological activity. Nat Prod Rep. 23:1007–1045. 2006.PubMed/NCBI
|
|
4
|
Wang JC: Cellular roles of DNA
topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol.
3:430–440. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marchand C, Antony S, Kohn KW, et al: A
novel norindenoisoquinoline structure reveals a common interfacial
inhibitor paradigm for ternary trapping of the topoisomerase I-DNA
covalent complex. Mol Cancer Ther. 5:287–295. 2006. View Article : Google Scholar
|
|
6
|
Urasaki Y, Laco G, Takebayashi Y, Bailly
C, Kohlhagen G and Pommier Y: Use of camptothecin-resistant
mammalian cell lines to evaluate the role of topoisomerase I in the
antiproliferative activity of the indolocarbazole, NB-506, and its
topoisomerase I binding site. Cancer Res. 61:504–508.
2001.PubMed/NCBI
|
|
7
|
Arakawa Y, Suzuki H, Saito S and Yamada H:
Novel missense mutation of the DNA topoisomerase I gene in
SN-38-resistant DLD-1 cells. Mol Cancer Ther. 5:502–508. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sirikantaramas S, Yamazaki M and Saito K:
Mutations in topoisomerase I as a self-resistance mechanism
coevolved with the production of the anticancer alkaloid
camptothecin in plants. Proc Natl Acad Sci USA. 105:6782–6786.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rasheed ZA and Rubin EH: Mechanisms of
resistance to topoisomerase I-targeting drugs. Oncogene.
22:7296–7304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Urasaki Y, Laco GS, Pourquier P, et al:
Characterization of a novel topoisomerase I mutation from a
camptothecin-resistant human prostate cancer cell line. Cancer Res.
61:1964–1969. 2001.PubMed/NCBI
|
|
11
|
Bonven BJ, Gocke E and Westergaard O: A
high affinity topoisomerase I binding sequence is clustered at
DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell.
41:541–551. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen TR, Dorotinsky CS, McGuire LJ, Macy
ML and Hay RJ: DLD-1 and HCT-15 cell lines derived separately from
colorectal carcinomas have totally different chromosome changes but
the same genetic origin. Cancer Genet Cytogenet. 81:103–108. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moisan F, Longy M, Robert J and Le Morvan
V: Identification of gene polymorphisms of human DNA topoisomerase
I in the National Cancer Institute panel of human tumour cell
lines. Br J Cancer. 95:906–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toyoda E, Kurosawa A, Fujii M and Adachi
N: Heterozygous disruption of the DNA topoisomerase I gene confers
cellular resistance to camptothecin in human cells. Biol Pharm
Bull. 32:724–727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miao ZH, Player A, Shankavaram U, et al:
Nonclassic functions of human topoisomerase I: genome-wide and
pharmacologic analyses. Cancer Res. 67:8752–8761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McClendon AK, Rodriguez AC and Osheroff N:
Human topoisomerase IIα rapidly relaxes positively supercoiled DNA:
implications for enzyme action ahead of replication forks. J Biol
Chem. 280:39337–39345. 2005.
|
|
17
|
Redinbo MR, Stewart L, Kuhn P, Champoux JJ
and Hol WG: Crystal structures of human topoisomerase I in covalent
and noncovalent complexes with DNA. Science. 279:1504–1513. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stewart L, Redinbo MR, Qiu X, Hol WG and
Champoux JJ: A model for the mechanism of human topoisomerase I.
Science. 279:1534–1541. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chrencik JE, Staker BL, Burgin AB, et al:
Mechanisms of camptothecin resistance by human topoisomerase I
mutations. J Mol Biol. 339:773–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laco GS, Collins JR, Luke BT, et al: Human
topoisomerase I inhibition: docking camptothecin and derivatives
into a structure-based active site model. Biochemistry.
41:1428–1435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakagawa H, Saito H, Ikegami Y,
Aida-Hyugaji S, Sawada S and Ishikawa T: Molecular modeling of new
camptothecin analogues to circumvent ABCG2-mediated drug resistance
in cancer. Cancer Lett. 234:81–89. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Komatani H, Kotani H, Hara Y, et al:
Identification of breast cancer resistant protein/mitoxantrone
resistance/placenta-specific, ATP-binding cassette transporter as a
transporter of NB-506 and J-107088, topoisomerase I inhibitors with
an indolocarbazole structure. Cancer Res. 61:2827–2832. 2001.
|
|
23
|
Pommier Y: Topoisomerase I inhibitors:
camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang LF, Ting CY, Lo CK, et al:
Identification of mutations at DNA topoisomerase I responsible for
camptothecin resistance. Cancer Res. 57:1516–1522. 1997.PubMed/NCBI
|
